In the total of 186 endometrioid endometrial carcinomas and 42 serous endometrial carcinomas, TP53 mutation was noted in 27 (15%) and 37 (88%) cases, respectively. This evidence concerns the gene TP53 and endometrial endometrioid carcinoma.